Two-way pharmacokinetic interaction studies between saxagliptin and cytochrome P450 substrates or inhibitors: simvastatin, diltiazem extended-release, and ketoconazole | Zendy

Chirag Patel | Zendy; Li Li | Zendy; Suzette Girgis | Zendy; David M. Kornhauser | Zendy; Ernst U. Frevert | Zendy; David W. Boulton | Zendy

Open Access

Two-way pharmacokinetic interaction studies between saxagliptin and cytochrome P450 substrates or inhibitors: simvastatin, diltiazem extended-release, and ketoconazole

Author(s) -

Chirag Patel,

Li Li,

Suzette Girgis,

David M. Kornhauser,

Ernst U. Frevert,

David W. Boulton

Publication year - 2011

Publication title -

clinical pharmacology advances and applications

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.685

H-Index - 27

ISSN - 1179-1438

DOI - 10.2147/cpaa.s15227

Subject(s) - ketoconazole , diltiazem , simvastatin , pharmacology , pharmacokinetic interaction , pharmacokinetics , saxagliptin , cyp3a4 , cyp3a , cytochrome p450 , chemistry , drug interaction , cytochrome , drug drug interaction , medicine , biochemistry , metabolism , enzyme , calcium , antifungal , metformin , dermatology , insulin , organic chemistry , sitagliptin

Many medicines, including several cholesterol-lowering agents (eg, lovastatin, simvastatin), antihypertensives (eg, diltiazem, nifedipine, verapamil), and antifungals (eg, ketoconazole) are metabolized by and/or inhibit the cytochrome P450 (CYP) 3A4 metabolic pathway. These types of medicines are commonly coprescribed to treat comorbidities in patients with type 2 diabetes mellitus (T2DM) and the potential for drug-drug interactions of these medicines with new medicines for T2DM must be carefully evaluated.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research